<p>CARLSBAD, Calif., <chron>Jan. 29</chron> /CNW/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has acquired 1,075,000 common shares of iCo Therapeutics Inc. ("iCo") pursuant to the exercise of 1,075,000 common share purchase warrants ("Warrants") issued to Isis in connection with a private placement of units of iCo on <chron>February 9, 2009</chron>. Each whole Warrant was exercisable at <money>$0.30</money> per share until <chron>February 10, 2010</chron>.</p>
<p>Following exercise of the Warrants, Isis owns an aggregate of 5,030,900 common shares of iCo, representing approximately 12.5% of iCo's issued and outstanding common shares.</p>
<p>The common shares were acquired for investment purposes. Isis may increase or decrease its ownership of securities of iCo depending upon future market conditions.</p>
ABOUT ISIS PHARMACEUTICALS, INC.
<p>Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at <a href="http://www.isispharm.com">www.isispharm.com</a>.</p>
For further information: For further information: Kristina Lemonidis, Director, Investor Relations of Isis Pharmaceuticals, Inc., +1-760-603-2490 Web Site: http://www.isispharm.com